- Home
- USEA vs IPA Comparison
USEA vs IPA Comparison
Compare USEA & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- IPA
- Stock Information
- Founded
- USEA 2004
- IPA 1983
- Country
- USEA Greece
- IPA Canada
- Employees
- USEA N/A
- IPA N/A
- Industry
- USEA Marine Transportation
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- IPA Health Care
- Exchange
- USEA Nasdaq
- IPA Nasdaq
- Market Cap
- USEA 15.1M
- IPA 15.3M
- IPO Year
- USEA N/A
- IPA 2017
- Fundamental
- Price
- USEA $1.87
- IPA $0.53
- Analyst Decision
- USEA Strong Buy
- IPA Strong Buy
- Analyst Count
- USEA 1
- IPA 2
- Target Price
- USEA $6.00
- IPA $5.00
- AVG Volume (30 Days)
- USEA 74.3K
- IPA 422.7K
- Earning Date
- USEA 02-18-2025
- IPA 03-13-2025
- Dividend Yield
- USEA 16.09%
- IPA N/A
- EPS Growth
- USEA N/A
- IPA N/A
- EPS
- USEA N/A
- IPA N/A
- Revenue
- USEA $46,160,000.00
- IPA $17,272,336.00
- Revenue This Year
- USEA $27.55
- IPA $1.88
- Revenue Next Year
- USEA $5.76
- IPA $9.90
- P/E Ratio
- USEA N/A
- IPA N/A
- Revenue Growth
- USEA 11.18
- IPA 6.36
- 52 Week Low
- USEA $1.63
- IPA $0.33
- 52 Week High
- USEA $3.00
- IPA $2.60
- Technical
- Relative Strength Index (RSI)
- USEA 54.04
- IPA 58.77
- Support Level
- USEA $1.73
- IPA $0.43
- Resistance Level
- USEA $1.82
- IPA $0.59
- Average True Range (ATR)
- USEA 0.08
- IPA 0.07
- MACD
- USEA 0.03
- IPA 0.01
- Stochastic Oscillator
- USEA 90.38
- IPA 71.48
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.